Log in

OTCMKTS:ZYXIZynex Stock Price, Forecast & News

$17.04
+0.22 (+1.31 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.69
Now: $17.04
$17.43
50-Day Range
$16.82
MA: $22.72
$28.58
52-Week Range
$7.51
Now: $17.04
$29.73
Volume681,015 shs
Average Volume806,090 shs
Market Capitalization$591.39 million
P/E Ratio77.45
Dividend YieldN/A
Beta1.05
Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Read More
Zynex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZYXI
CUSIPN/A
Phone303-703-4906

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.43 million
Cash Flow$0.95 per share
Book Value$0.15 per share

Profitability

Net Income$7.36 million

Miscellaneous

EmployeesN/A
Market Cap$591.39 million
Next Earnings DateN/A
OptionableNot Optionable
$17.04
+0.22 (+1.31 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zynex (OTCMKTS:ZYXI) Frequently Asked Questions

How has Zynex's stock been impacted by COVID-19 (Coronavirus)?

Zynex's stock was trading at $11.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZYXI stock has increased by 53.7% and is now trading at $17.04.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Zynex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zynex
.

How were Zynex's earnings last quarter?

Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings data on Tuesday, July, 28th. The company reported $0.09 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.00. The business earned $19.26 million during the quarter, compared to analyst estimates of $19.12 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%.
View Zynex's earnings history
.

What guidance has Zynex issued on next quarter's earnings?

Zynex updated its third quarter 2020 After-Hours earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $22.3-22.8 million, compared to the consensus revenue estimate of $22.06 million.

What price target have analysts set for ZYXI?

4 brokers have issued 12 month price targets for Zynex's shares. Their forecasts range from $22.50 to $30.00. On average, they expect Zynex's share price to reach $26.38 in the next twelve months. This suggests a possible upside of 54.8% from the stock's current price.
View analysts' price targets for Zynex
.

Has Zynex been receiving favorable news coverage?

Media headlines about ZYXI stock have been trending very positive on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zynex earned a news impact score of 4.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Zynex
.

Who are some of Zynex's key competitors?

What other stocks do shareholders of Zynex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include Aurora Cannabis (ACB), FuelCell Energy (FCEL), Pfizer (PFE), AT&T (T), Exxon Mobil (XOM), Aytu Bioscience (AYTU), BioDelivery Sciences International (BDSI), Canopy Growth (CGC), IBM (IBM) and Melinta Therapeutics (MLNT).

Who are Zynex's key executives?

Zynex's management team includes the following people:
  • Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
  • Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
  • Mr. David B. Mogill, VP of Operations
  • Mr. Robert Bird, VP of Marketing
  • Mr. Steve Siefring, Director of Bus. Devel.

What is Zynex's stock symbol?

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

Who are Zynex's major shareholders?

Zynex's stock is owned by a number of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.67%), Principal Financial Group Inc. (0.33%), Cadence Capital Management LLC (0.25%), Genesee Capital Advisors LLC (0.24%), Mackay Shields LLC (0.24%) and Mutual of America Capital Management LLC (0.22%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard.
View institutional ownership trends for Zynex
.

Which institutional investors are selling Zynex stock?

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, and WINTON GROUP Ltd.
View insider buying and selling activity for Zynex
.

Which institutional investors are buying Zynex stock?

ZYXI stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Genesee Capital Advisors LLC, Mackay Shields LLC, Mutual of America Capital Management LLC, New York State Teachers Retirement System, Swiss National Bank, Trexquant Investment LP, and SG Americas Securities LLC.
View insider buying and selling activity for Zynex
.

How do I buy shares of Zynex?

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zynex's stock price today?

One share of ZYXI stock can currently be purchased for approximately $17.04.

How big of a company is Zynex?

Zynex has a market capitalization of $591.39 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis.

What is Zynex's official website?

The official website for Zynex is www.zynexmed.com.

How can I contact Zynex?

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.